Authors


Soyal R. Momin, MS, MBA

Latest:

Distal Upper and Lower Limb Fractures Associated With Thiazolidinedione Use

This study demonstrates that patients with diabetes taking thiazolidinediones have higher proportions of distal upper and lower limb fractures than those not taking the drug.


Seth W. Glickman, MD, MBA

Latest:

The Mis-Measure of Physician Performance

We discuss our concerns about tying physician performance to CG-CAHPS scores and suggest an alternative approach to facilitate translation of service excellence into clinical practice.







Karen K. Maylor, RN

Latest:

No Time to Waste: Decreasing Patient Wait Times for Chemotherapy Administration Using Automated Prioritization in an Oncology Pharmacy System

Using a prioritization algorithm in an oncology pharmacy system at the Johns Hopkins University, patient wait times for chemotherapy administration were significantly decreased.


Dan Berlowitz, MD, MPH

Latest:

Anticoagulation in Atrial Fibrillation: Impact of Mental Illness

Atrial fibrillation patients with mental health conditions are less likely to be eligible for warfarin receipt, and those who are eligible receive warfarin at lower rates.


Joseph A. Stankaitis, MD, MPH

Latest:

Addressing Health Care Disparities Using a Health Plan Quality Measures Index

The Health Insurance Disparities Index allows stakeholders to assess progress in addressing health care disparities using publicly available, validated, reported health plan quality metrics results.



Michael Sherman, MD

Latest:

Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.


Glenda Frederick, BA

Latest:

Medication Burden in Patients With Acute Coronary Syndromes

Patients endure heavy medication complexity following hospital discharge for acute coronary syndrome.


Danielle L. Kruger, BA

Latest:

Hepatitis C Care Cascade Among Persons Born 1945-1965: 3 Medical Centers

In this analysis of patients with newly diagnosed hepatitis C, linkage to care was largely successful in the 1945-1965 birth cohort, but treatment initiation remained low. Check out our website’s new table/figure pop-up feature! Click on the name of a table or figure in the text to see it in your browser.


M. Kristina Wharton, MPA, MPH

Latest:

Ensuring Access to Prescription Medications in the Post-ACA Healthcare Access Landscape: The Essential Role of FQHCs in the Safety Net for the Underinsured

The role of federally qualified health centers is evaluated in serving uninsured patients and providing need-based, reduced-cost prescription medications in the post–Affordable Care Act landscape.








Joseph S. Ross, MD

Latest:

Adoption of New Agents and Changes in Treatment Patterns for Hepatitis C: 2010-2014

New hepatitis C medications have been quickly adopted into practice and increased treatment rate. The median out-of-pocket costs of new medications were relatively low.


Candace T. Peterson, PhD

Latest:

A Team Approach to Systematic Behavioral Screening and Intervention

Expanding primary care teams with trained and supported paraprofessionals enables systematic delivery of widely recommended, evidence-based, cost-saving alcohol, drug, and depression screening and intervention services.




Patricia Fontaine, MD, MS

Latest:

Patient-Centered Medical Home Cost Reductions Limited to Complex Patients

From 2005 to 2009, improved clinical practice systems were associated with cost reductions only for medically complex patients.



Jennifer S. Myers, MD

Latest:

Chasing High Performance: Best Business Practices for Using Health Information Technology to Advance Patient Safety

This commentary reflects how high-performing healthcare organizations use health information technology to advance patient safety.



Anish S. Patel, BS

Latest:

Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?

The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo